22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
Under the Americans with Disabilities Act (“ADA”), an employee is entitled to a reasonable accommo...
Read More >
Employee burnout is now an officially diagnosable condition. According to the World Health Organizat...
Read More >
On February 1, 2021, the Federal Trade Commission (FTC) announced its revised annual threshold that ...
Read More >
The SEC has adopted amendments to the financial disclosure requirements in Regulation S-X for acquis...
Read More >
On January 13, 2020, the U.S. Department of Labor issued its final rule to update and revise the dep...
Read More >
In a year marked by unexpected challenges and rapid change, staying connected with industry peers an...
Read More >